Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/51604
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
- AM - ILMD - Artigos de Periódicos [335]
- IOC - Artigos de Periódicos [12818]
Metadata
Show full item record
REDUCED NEUTRALIZATION OF SARS-COV-2 B.1.617 BY VACCINE AND CONVALESCENT SERUM
Neutralização reduzida
Vacina
Soro convalescente
Rede Genômica Fiocruz
GENOMAHCOV
COVID-19
https://www.arca.fiocruz.br/handle/icict/47927
Author
Liu, Chang
Ginn, Helen M.
Dejnirattisai, Wanwisa
Supasa, Piyada
Wang, Beibei
Tuekprakhon, Aekkachai
Nutalai, Rungtiwa
Zhou, Daming
Mentzer, Alexander J.
Zhao, Yuguang
Duyvesteyn, Helen M.E.
López-Camacho, César
Slon-Campos, Jose
Walter, Thomas S.
Skelly, Donal
Johnson, Sile Ann
Ritter, Thomas G.
Mason, Chris
Clemens, Sue Ann Costa
Naveca, Felipe Gomes
Nascimento, Valdinete
Nascimento, Fernanda
Costa, Cristiano Fernandes da
Resende, Paola Cristina
Pauvolid-Correa, Alex
Siqueira, Marilda Agudo Mendonça Teixeira de
Dold, Christina
Temperton, Nigel
Dong, Tao
Ginn, Helen M.
Dejnirattisai, Wanwisa
Supasa, Piyada
Wang, Beibei
Tuekprakhon, Aekkachai
Nutalai, Rungtiwa
Zhou, Daming
Mentzer, Alexander J.
Zhao, Yuguang
Duyvesteyn, Helen M.E.
López-Camacho, César
Slon-Campos, Jose
Walter, Thomas S.
Skelly, Donal
Johnson, Sile Ann
Ritter, Thomas G.
Mason, Chris
Clemens, Sue Ann Costa
Naveca, Felipe Gomes
Nascimento, Valdinete
Nascimento, Fernanda
Costa, Cristiano Fernandes da
Resende, Paola Cristina
Pauvolid-Correa, Alex
Siqueira, Marilda Agudo Mendonça Teixeira de
Dold, Christina
Temperton, Nigel
Dong, Tao
Affilliation
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK / Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
Diamond Light Source Ltd., Harwell Science & Innovation Campus, Didcot, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK / Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK / Peter Medawar Building for Pathogen Research, Oxford, UK / Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Peter Medawar Building for Pathogen Research, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Institute of Global Health, University of Siena, Siena, Italy / Department of Paediatrics, University of Oxford, Oxford, UK.
Fundação Oswaldo Cruz. Instituto Leônidas e Maria Deane. Laboratório de Ecologia de Doenças Transmissíveis na Amazônia. Manaus, AM, Brasil
Fundação Oswaldo Cruz. Instituto Leônidas e Maria Deane. Laboratório de Ecologia de Doenças Transmissíveis na Amazônia. Manaus, AM, Brasil
Fundação Oswaldo Cruz. Instituto Leônidas e Maria Deane. Laboratório de Ecologia de Doenças Transmissíveis na Amazônia. Manaus, AM, Brasil
Fundação de Vigilãncia em Saúde do Amazonas, Manaus, AM, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz Laboratório de Vírus Respiratório e do Sarampo. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz Laboratório de Vírus Respiratório e do Sarampo. Rio de Janeiro, RJ, Brasil / Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz Laboratório de Vírus Respiratório e do Sarampo. Rio de Janeiro, RJ, Brasil.
NIHR Oxford Biomedical Research Centre, Oxford, UK / Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent and Greenwich, Chatham Maritime, Kent ME4 4TB, UK.
Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK / Nuffield Department of Medicine, University of Oxford, Oxford, UK / MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK,
Diamond Light Source Ltd., Harwell Science & Innovation Campus, Didcot, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK / Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK / Peter Medawar Building for Pathogen Research, Oxford, UK / Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Peter Medawar Building for Pathogen Research, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Institute of Global Health, University of Siena, Siena, Italy / Department of Paediatrics, University of Oxford, Oxford, UK.
Fundação Oswaldo Cruz. Instituto Leônidas e Maria Deane. Laboratório de Ecologia de Doenças Transmissíveis na Amazônia. Manaus, AM, Brasil
Fundação Oswaldo Cruz. Instituto Leônidas e Maria Deane. Laboratório de Ecologia de Doenças Transmissíveis na Amazônia. Manaus, AM, Brasil
Fundação Oswaldo Cruz. Instituto Leônidas e Maria Deane. Laboratório de Ecologia de Doenças Transmissíveis na Amazônia. Manaus, AM, Brasil
Fundação de Vigilãncia em Saúde do Amazonas, Manaus, AM, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz Laboratório de Vírus Respiratório e do Sarampo. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz Laboratório de Vírus Respiratório e do Sarampo. Rio de Janeiro, RJ, Brasil / Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz Laboratório de Vírus Respiratório e do Sarampo. Rio de Janeiro, RJ, Brasil.
NIHR Oxford Biomedical Research Centre, Oxford, UK / Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent and Greenwich, Chatham Maritime, Kent ME4 4TB, UK.
Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK / Nuffield Department of Medicine, University of Oxford, Oxford, UK / MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK,
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with
variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased
transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent
and has been designated a variant of concern in the United Kingdom. Here we study the ability
of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement
this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic
space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related
strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and
P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected
previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides
important new insights for immunization policy with future variant vaccines in non-immune populations.
Keywords in Portuguese
SARS-CoV-2 B.1.617Neutralização reduzida
Vacina
Soro convalescente
Rede Genômica Fiocruz
GENOMAHCOV
COVID-19
Share